The present invention provides for compounds of Formula I-I and embodiments and salts thereof for the treatment of diseases (e.g., neurodegenerative diseases). R.sup.1, R.sup.2, R.sup.3, X.sup.1, X.sup.2, A and Cy variable in Formula I-I all have the meaning as defined herein.

##STR00001##

The present invention provides for compounds of Formula I-I and embodiments and salts thereof for the treatment of diseases (e.g., neurodegenerative diseases). R.sup.1, R.sup.2, R.sup.3, X.sup.1, X.sup.2, A and Cy variable in Formula I-I all have the meaning as defined herein.

##STR00001##

The present invention provides for compounds of Formula I and embodiments and salts thereof for the treatment of diseases (e.g., neurodegenerative diseases). R.sup.1, R.sup.2, R.sup.3, X.sup.1, X.sup.2, A and Cy variable in Formula all have the meaning as defined herein.

##STR00001##

The present invention provides for compounds of Formula I and embodiments and salts thereof for the treatment of diseases (e.g., neurodegenerative diseases). R.sup.1, R.sup.2, R.sup.3, X.sup.1, X.sup.2, A and Cy variable in Formula all have the meaning as defined herein.

##STR00001##

The present invention relates to novel oxazolidinones (Formula I): or a pharmaceutically acceptable salt having ring A characterized by N-containing monocyclic, bicyclic or spirocyclic substituents, to their preparation, and to their use as drugs for treating Mycobacterium tuberculosis and other microbial infections, either alone or in combination with other anti-infective treatments.

##STR00001##

The present invention relates to novel oxazolidinones (Formula I): or a pharmaceutically acceptable salt having ring A characterized by N-containing monocyclic, bicyclic or spirocyclic substituents, to their preparation, and to their use as drugs for treating Mycobacterium tuberculosis and other microbial infections, either alone or in combination with other anti-infective treatments.

##STR00001##

Disclosed is a compound of formula (I) in which a, R.sup.1-R.sup.5 and X.sup.1 are as described herein. Also disclosed are a pharmaceutical composition containing the compound and a method of using the compound for treating cancer, such as renal cancer.

The present invention generally relates to electrochromic compounds and the uses thereof, particularly to series of fluoroalkyl 3,4-dioxythiophene compounds and their electrochromic polymers or co-polymers. Both compositions and process for manufacturing thereof are in the scope of this invention.

The present invention generally relates to electrochromic compounds and the uses thereof, particularly to series of fluoroalkyl 3,4-dioxythiophene compounds and their electrochromic polymers or co-polymers. Both compositions and process for manufacturing thereof are in the scope of this invention.

The present invention provides for compounds of Formula I and embodiments and salts thereof for the treatment of diseases (e.g., neurodegenerative diseases). R.sup.1, R.sup.2, R.sup.3, X.sup.1, X.sup.2, A and Cy variable in Formula all have the meaning as defined herein. ##STR00001##